Last reviewed · How we verify
Synergy for Group B Streptococcal Septicemia
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Gentamicin · Merck & Co.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Synergy for Group B Streptococcal Septicemia patent landscape — cliff calendar, originator estates, attackable patents
- Synergy for Group B Streptococcal Septicemia treatment landscape brief
- Synergy for Group B Streptococcal Septicemia treatment updates RSS
Frequently asked questions about Synergy for Group B Streptococcal Septicemia
What drugs treat Synergy for Group B Streptococcal Septicemia?
Tracked treatments include Ramycin, Garamycin, Gentamicin.
What is the treatment for Synergy for Group B Streptococcal Septicemia?
Standard treatment for Synergy for Group B Streptococcal Septicemia includes Ramycin, Garamycin, Gentamicin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Synergy for Group B Streptococcal Septicemia patent cliff · Synergy for Group B Streptococcal Septicemia CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Gentamicin · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing